花旗发表研究报告指，平安好医生(01833.HK) 管理层预计收入年均复合增长率将达到双位数，预计中期净利润率也将达到双位数增长。管理层预期，受惠供应链效率提升、集中采购、市场收入增加以及人工智能应用和数码化管理控制营运费用等，其盈利能力将有所提升。在并购方面，公司专注于医疗保健和老年护理领域的目标。
该行将平安好医生今年至2027年收入预测分别上调3%、4%及5%，每股盈利预测各上调40%、47%及49%，同时将其目标价由12元上调至20元，评级“买入”，并视平安好医生为其首选股之一。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-22 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.